Obsidian Therapeutics, Inc. in brief
Obsidian Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. Its shares trade under the symbol OBX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Obsidian Therapeutics, Inc. timeline
- 2026
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed Obsidian Therapeutics, Inc.Formerly Gazelle Parent, Inc..
Events of Obsidian Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-106M | $-101M | — |
| Dec 2024 | — | — | $-91M | $-83M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-90M | $0M | $-90M | $-7.22 | — |
| Dec 2024 | $-75M | $1M | $-76M | $-6.47 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-51M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 28, 2026S-1IPO registration
- Aug 14, 20268-K/ACurrent report (amended)
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Results of operations · Unregistered share sale · Auditor change · Change in control · Directors or officers changed · Bylaws amended · Regulation FD disclosure
Official filings of Obsidian Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-106 M
- Net income
- $-101 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $89 M
- Total liabilities
- $17 M
- Total equity
- $-266 M
As of December-2025
Top 60 institutional investors in Obsidian Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 5,957,103 | New | 9.64% | $82 M | Nov 16, 2026 |
| 2 | Atlas Venture Life Science Advisors, LLC | 4,503,149 | New | 7.29% | $62 M | Nov 10, 2026 |
| 3 | Paradigm Biocapital Advisors LP | 4,155,214 | New | 6.73% | $57 M | Nov 16, 2026 |
| 4 | Novo Holdings A/s | 3,123,992 | New | 5.06% | $43 M | Nov 16, 2026 |
| 5 | Trails Edge Capital Partners, LP | 2,495,660 | New | 4.04% | $34 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 2,441,332 | New | 3.95% | $34 M | Nov 13, 2026 |
| 7 | Octagon Capital Advisors LP | 2,414,610 | New | 3.91% | $33 M | Nov 16, 2026 |
| 8 | TCG Crossover Management, LLC | 2,196,138 | New | 3.56% | $30 M | Nov 16, 2026 |
| 9 | Deep Track Capital, LP | 2,120,050 | New | 3.43% | $29 M | Nov 16, 2026 |
| 10 | Citadel Advisors LLC | 1,947,843 | New | 3.15% | $27 M | Nov 16, 2026 |
| 11 | Blue Owl Capital Holdings LP | 1,482,767 | New | 2.40% | $20 M | Nov 13, 2026 |
| 12 | Spruce Street Capital LP | 1,249,943 | New | 2.02% | $17 M | Nov 13, 2026 |
| 13 | Alphabet Inc. | 1,224,869 | New | 1.98% | $17 M | Nov 6, 2026 |
| 14 | Nantahala Capital Management, LLC | 1,199,796 | New | 1.94% | $16 M | Nov 13, 2026 |
| 15 | Price T Rowe Associates Inc /MD/ | 1,057,455 | New | 1.71% | $15 M | Nov 16, 2026 |
| 16 | Nan Fung Group Holdings Ltd | 918,765 | New | 1.49% | $13 M | Nov 13, 2026 |
| 17 | Foresite Capital Management VI LLC | 916,063 | New | 1.48% | $13 M | Nov 16, 2026 |
| 18 | Caligan Partners LP | 886,281 | New | 1.43% | $12 M | Nov 16, 2026 |
| 19 | Pivotal bioVenture Partners Investment Advisor LLC | 860,343 | New | 1.39% | $12 M | Nov 13, 2026 |
| 20 | Samsara Biocapital, LLC | 837,173 | New | 1.36% | $11 M | Nov 16, 2026 |
| 21 | Redmile Group, LLC | 833,157 | New | 1.35% | $11 M | Nov 16, 2026 |
| 22 | BlackRock, Inc. | 775,759 | New | 1.26% | $11 M | Nov 13, 2026 |
| 23 | Janus Henderson Group Ltd. | 728,700 | — | 1.18% | $10 M | Nov 16, 2026 |
| 24 | Eventide Asset Management, LLC | 624,972 | New | 1.01% | $9 M | Nov 13, 2026 |
| 25 | Balyasny Asset Management L.P. | 587,724 | New | 0.95% | $8 M | Nov 16, 2026 |
Show all 60: investors 26 to 60
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Longaeva Partners L.P. | 499,963 | New | 0.81% | $7 M | Nov 16, 2026 |
| 27 | Geode Capital Management, LLC | 483,438 | New | 0.78% | $7 M | Nov 6, 2026 |
| 28 | Revelation Capital Management, LLC | 428,346 | New | 0.69% | $6 M | Nov 2, 2026 |
| 29 | Kalehua Capital Management LLC | 416,649 | New | 0.67% | $6 M | Nov 13, 2026 |
| 30 | Adage Capital Partners GP, L.L.C. | 416,648 | New | 0.67% | $6 M | Nov 16, 2026 |
| 31 | Woodline Partners LP | 354,064 | New | 0.57% | $5 M | Nov 16, 2026 |
| 32 | Ally Bridge Group (NY) LLC | 302,449 | New | 0.49% | $4 M | Nov 16, 2026 |
| 33 | Charles Schwab Investment Management Inc | 301,706 | New | 0.49% | $4 M | Nov 16, 2026 |
| 34 | Vanguard Fiduciary Trust Co | 291,071 | New | 0.47% | $4 M | Nov 13, 2026 |
| 35 | State Street Corp | 223,487 | New | 0.36% | $3 M | Nov 12, 2026 |
| 36 | UBS Group AG | 199,207 | New | 0.32% | $3 M | Nov 10, 2026 |
| 37 | Millennium Management LLC | 165,336 | New | 0.27% | $2 M | Nov 16, 2026 |
| 38 | Ikarian Capital, LLC | 158,942 | New | 0.26% | $2 M | Nov 16, 2026 |
| 39 | Boothbay Fund Management, LLC | 141,651 | New | 0.23% | $2 M | Nov 16, 2026 |
| 40 | TD Asset Management Inc | 140,520 | New | 0.23% | $2 M | Nov 13, 2026 |
| 41 | Alyeska Investment Group, L.P. | 125,008 | New | 0.20% | $2 M | Nov 16, 2026 |
| 42 | Northern Trust Corp | 102,524 | New | 0.17% | $1 M | Nov 16, 2026 |
| 43 | Opaleye Management Inc. | 75,755 | New | 0.12% | $1 M | Nov 16, 2026 |
| 44 | RTW Investments, LP | 67,706 | New | 0.11% | $1 M | Nov 16, 2026 |
| 45 | Seven Grand Managers, LLC | 52,000 | New | 0.08% | $1 M | Nov 16, 2026 |
| 46 | Goldman Sachs Group Inc | 42,912 | New | 0.07% | $1 M | Nov 16, 2026 |
| 47 | GTS Securities LLC | 29,122 | New | 0.05% | $0 M | Nov 16, 2026 |
| 48 | Aster Capital Management (DIFC) Ltd | 26,236 | New | 0.04% | $0 M | Nov 12, 2026 |
| 49 | Seven Fleet Capital Management LP | 23,077 | New | 0.04% | $0 M | Nov 16, 2026 |
| 50 | Vanguard Global Advisers, LLC | 17,175 | New | 0.03% | $0 M | Nov 13, 2026 |
| 51 | Bank of New York Mellon Corp | 11,163 | New | 0.02% | $0 M | Nov 5, 2026 |
| 52 | Tower Research Capital LLC (TRC) | 1,563 | New | 0.00% | $0 M | Nov 16, 2026 |
| 53 | Morgan Stanley | 629 | New | 0.00% | $0 M | Nov 13, 2026 |
| 54 | Citigroup Inc | 419 | New | 0.00% | $0 M | Nov 4, 2026 |
| 55 | Toronto Dominion Bank | 351 | New | 0.00% | $0 M | Nov 16, 2026 |
| 56 | Nuveen, LLC | 209 | New | 0.00% | $0 M | Nov 10, 2026 |
| 57 | Strategic Financial Concepts, LLC | 125 | New | 0.00% | $0 M | Nov 16, 2026 |
| 58 | Group One Trading LLC | 26 | New | 0.00% | $0 M | Nov 10, 2026 |
| 59 | Danske Bank A/s | 1 | New | 0.00% | $0 M | Nov 9, 2026 |
| 60 | SBI Securities Co., Ltd. | 1 | New | 0.00% | $0 M | Oct 22, 2026 |
Markets and events: Obsidian Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-08-17 13:30 UTC, code LUDP, resumed 13:40 UTC
- 2026-08-13 15:00 UTC, code LUDP, resumed 15:05 UTC
- 2026-08-13 14:33 UTC, code LUDP, resumed 14:43 UTC
- 2026-08-10 15:09 UTC, code LUDP, resumed 15:19 UTC
- 2026-08-05 13:49 UTC, code LUDP, resumed 13:59 UTC
Fails to deliver
- : 1,044 shares at $14.52
- : 648 shares at $14.59
- : 492 shares at $13.86
- : 474 shares at $13.93
- : 1,230 shares at $13.25
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Obsidian Therapeutics, Inc. scorecard#
Passes 1 of the 4 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-7.22 vs -6.47Diluted EPS -7.22 in fiscal 2025 against -6.47 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 1
- ✗Profitable in the newest year-$101 MNet income -$101 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities5.3×Current ratio 5.31 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year8.5%Diluted shares up 8.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at Obsidian Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Results announced 2
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
H-1B hiring at Obsidian Therapeutics, Inc.#
5 labor condition applications certified in fiscal 2026 for 5 positions, at a median wage of $110 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist, Cell TherapyMolecular and Cellular Biologists | 2 | $107 K |
| Associate Scientist, Analytical DevelopmentMedical Scientists, Except Epidemiologists | 1 | $110 K |
| Scientist, Viral Vector Analytical DevelopmentMolecular and Cellular Biologists | 1 | $135 K |
| Senior QA Operations ManagerRegulatory Affairs Specialists | 1 | $142 K |
Where: Bedford, MA 2 · Cambridge, MA 2 · Downington, PA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 5 | 5 | $110 K | 5 |
| FY2025 | 3 | 3 | $110 K | 3 |
| FY2023 | 3 | 3 | $89 K | 3 |
| FY2022 | 2 | 2 | $135 K | 2 |
| FY2021 | 1 | 1 | $180 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Obsidian Therapeutics, Inc.
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Obsidian Therapeutics, Inc.🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Obsidian Therapeutics, Inc.? Verify and update this profile — free
Show Obsidian Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.